EudraVigilance

EudraVigilance, officially known as the European Union Drug Regulating Authorities Pharmacovigilance, is a comprehensive data processing network and management system that operates within the European Economic Area (EEA). Its primary function is to record, evaluate, and manage reports of suspected adverse reactions, both during the clinical development phase of new drugs and after they have received marketing authorisation.

Background

Established by the regulatory authorities of the European Union, EudraVigilance plays a crucial role in ensuring the safety and efficacy of medicinal products in the EEA. By collating data from various sources, it enables regulatory bodies to gain a broader understanding of potential risks associated with drugs, ensuring that decisions made about these drugs are well-informed and in the best interest of public health.

Key Functions

The European EudraVigilance system encompasses several core activities:

• Electronic exchange of Individual Case Safety Reports (ICSR): This process is standardized based on the ICH E2BM specifications, ensuring consistency in the reporting and evaluation of adverse drug reactions.

• EudraVigilance Clinical Trial Module (EVCTM): Specifically tailored for the reporting of Suspected Unexpected Serious Adverse Reactions (SUSARs) that may occur during clinical trials.

• EudraVigilance Post-Authorisation Module (EVPM): This module focuses on the collation and evaluation of ICSRs that are reported after a drug has been granted marketing authorisation.

• Early Detection of Safety Concerns: EudraVigilance plays a pivotal role in the early identification of potential safety signals arising from drugs that are currently on the market for human consumption.

• Continuous Monitoring and Evaluation: By consistently reviewing and assessing the adverse reactions reported, EudraVigilance helps in the ongoing evaluation of a drug's safety profile.

• Informed Decision Making: By providing a comprehensive overview of the adverse reaction profile of drugs, EudraVigilance aids the regulatory authorities in making evidence-based decisions regarding the safety and efficacy of drugs.

Significance

EudraVigilance represents a cornerstone of the European Union's approach to pharmacovigilance. Its intricate system ensures that potential safety concerns associated with medicinal products are quickly identified, thoroughly evaluated, and appropriately addressed, all with the ultimate goal of safeguarding public health within the European Economic Area.

See also

• Clinical trial
• Drug development
• EudraCT
• EudraGMP
• EudraLex
• EUDRANET
• EudraPharm
• European Clinical Research Infrastructures Network
• European Medicines Agency
• International Society of Pharmacovigilance
• Medication
• Pharmacovigilance
• Serious adverse event
• Uppsala Monitoring Centre
• Yellow Card Scheme

External links

• EudraVigilance

This article is a stub. You can help WikiMD by registering to expand it. Editing is available only to registered and verified users. WikiMD is a comprehensive, free health & wellness encyclopedia.